Clinical evaluation of Granisetron against nausea and vomiting induced by Carboplatin in oral cancer patients

—Multi-center study—

Abstract

In order to evaluate the clinical efficacy of granisetron as an antiemetic agent for the prevention of nausea and vomiting induced by carboplatin (CBDCA), a multi-center study has been conducted.
Thirty cases of patients with oral cancer were selected for this study from six hospitals, and to each patient 3 mg/body of granisetron was given intravenously immediately before CBDCA administration (200-350mg/m²) . The incidence and severity of nausea and vomiting were observed for a period of 5 days after administration of CBDCA.
Nausea occurred in 8 out of 30 patients, occurring slightly in 5 patients only on the first day as well as continuing in 3 patients for two or three days.
Only one patient complained of moderate nausea on the third day. Vomiting was observed in only one patient who vomited three times on the third day and once on the fourth day. This was the same patient who complained of moderate nausea.
In this study. 73.3% of patients were free from nausea and 96.7 % were free from vomiting. Concerning the efficacy of granisetron in this study, granisetron was considered to be “remarkably effective” in 96.7 % of patients and it was considered to be “effective” in 3.3 % of patients.